BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) Noema Pharma, aclinical-stage biotech company targeting debilitating central nervoussystem (CNS) disorders, today announced the appointment of VolkerKnappertz, M.D., as Executive Vice President of Research & Development.
We are excited to welcome Volker to Noema. Volker is a recognized leaderin drug development with a proven track record building and leadingResearch and Development organizations and obtaining market approvalsfor novel drugs, including Epidiolex for the treatment of raredevelopmental childhood onset forms of epilepsy. His experience andexpertise across CNS development will be pivotal as Noema enters atransformational year with readouts of multiple Phase 2 studies across ourpipeline.
Ilise Lombardo, M.D.
Chief Executive Officer of Noema Pharma
I am thrilled to join Noema and look forward to the continued clinicaldevelopment across the company’s multiple indications including seizuresin Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourettesyndrome and vasomotor symptoms plus CNS-mediated symptoms ofmenopause. Noema’s commitment to patients andinnovative approach to CNS disorders is proven by their late-stage clinicalpipeline and I look forward to working with the team to bring these first-in-disease therapeutics to patients in need.
Dr. Knappertz
Dr. Volker Knappertz has spent over 25 years in drug development and hasbeen involved in numerous Investigational New Drug (IND) filings andproduct approvals during his career. Prior to joining Noema, Dr. Knappertzserved as Executive Vice President of Research & Development (R&D) atAurinia Pharmaceuticals, where he led the entirety of R&D across multipleprograms targeting autoimmune diseases. Dr. Knappertz also served asExecutive Vice President of R&D and Chief Medical Officer at GWPharmaceuticals (acquired by Jazz Pharmaceuticals). During his time atGW, Dr. Knappertz was instrumental in driving the transformation of GWfrom a botanical pharmaceutical company to a fully integratedbiopharmaceutical company following the FDA approval of Epidiolex forthe treatment of rare developmental childhood onset forms of epilepsy. Inaddition, he played a role in several drug approvals and major businessdevelopment deals during his tenure in leadership positions at TevaPharmaceuticals, AstraZeneca and Bayer. Dr. Knappertz received hisdoctorate and Medical Degree from Cologne University and is a US boardcertified neurologist. He has served as Adjunct Professor in Neurology atthe University of Pennsylvania and Heinrich-Heine University in Düsseldorf.
Investor Contact
Argot Partners
Maeve Conneighton
212-600-1902
noema@argotpartners.com